JP2016540030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540030A5 JP2016540030A5 JP2016540981A JP2016540981A JP2016540030A5 JP 2016540030 A5 JP2016540030 A5 JP 2016540030A5 JP 2016540981 A JP2016540981 A JP 2016540981A JP 2016540981 A JP2016540981 A JP 2016540981A JP 2016540030 A5 JP2016540030 A5 JP 2016540030A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- vortioxetine
- nalmefene
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 239000011780 sodium chloride Substances 0.000 claims 20
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 10
- YQNWZWMKLDQSAC-UHFFFAOYSA-N Vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 10
- 229960002263 Vortioxetine Drugs 0.000 claims 10
- 229960005297 nalmefene Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000000996 additive Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
Claims (13)
- ナルメフェンまたはその薬学的に許容される塩、およびボルチオキセチンまたはその薬学的に許容される塩を、薬学的に許容される添加剤と一緒に含む医薬組成物。
- １〜３０ｍｇのナルメフェンまたはその薬学的に許容される塩を含む、請求項１に記載の医薬組成物。
- ５〜２０ｍｇのナルメフェンまたはその薬学的に許容される塩を含む、請求項２に記載の医薬組成物。
- １８ｍｇのナルメフェンまたはその薬学的に許容される塩を含む、請求項３に記載の医薬組成物。
- １〜３０ｍｇのボルチオキセチンまたはその薬学的に許容される塩に含む、請求項１〜４のいずれかに医薬組成物。
- ５〜２０ｍｇのボルチオキセチンまたはその薬学的に許容される塩を含む、請求項５に記載の医薬組成物。
- ５，１０，１５，または２０ｍｇのボルチオキセチンまたはその薬学的に許容される塩を含む、請求項６に記載の医薬組成物。
- １〜３０ｍｇのナルメフェンまたはその薬学的に許容される塩、および１〜３０ｍｇのボルチオキセチンまたはその薬学的に許容される塩を含む、請求項１に記載の医薬組成物。
- ５〜２０ｍｇのナルメフェンまたはその薬学的に許容される塩、および５〜２０ｍｇのボルチオキセチンまたはその薬学的に許容される塩を含む、請求項８に記載の医薬組成物。
- ナルメフェンまたはその薬学的に許容される塩を、ボルチオキセチンまたはその薬学的に許容される塩と一緒に含むキット。
- 前記ナルメフェンまたはその薬学的に許容される塩と、前記ボルチオキセチンまたはその薬学的に許容される塩との同時投与に適応している、請求項１０に記載のキット。
- 前記ナルメフェンまたはその薬学的に許容される塩と、前記ボルチオキセチンまたはその薬学的に許容される塩との別々の投与に適応している、請求項１０に記載のキット。
- メランコリアの特徴を伴う抑うつ障害の処置方法における使用のためのナルメフェンまたはその薬学的に許容される塩とボルチオキセチンまたはその薬学的に許容される塩。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300710 | 2013-12-20 | ||
| DKPA201300710 | 2013-12-20 | ||
| DKPA201400590 | 2014-10-16 | ||
| DKPA201400590 | 2014-10-16 | ||
| PCT/EP2014/078515 WO2015091833A1 (en) | 2013-12-20 | 2014-12-18 | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540030A JP2016540030A (ja) | 2016-12-22 |
| JP2016540030A5 true JP2016540030A5 (ja) | 2018-01-18 |
| JP6448645B2 JP6448645B2 (ja) | 2019-01-09 |
Family
ID=52146489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540981A Active JP6448645B2 (ja) | 2013-12-20 | 2014-12-18 | メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10376506B2 (ja) |
| EP (1) | EP3082815B1 (ja) |
| JP (1) | JP6448645B2 (ja) |
| KR (1) | KR20160093025A (ja) |
| CN (1) | CN105828821B (ja) |
| AU (1) | AU2014368548B2 (ja) |
| CA (1) | CA2933733A1 (ja) |
| CL (1) | CL2016001570A1 (ja) |
| ES (1) | ES2694352T3 (ja) |
| IL (1) | IL246253A0 (ja) |
| MX (1) | MX368870B (ja) |
| RU (1) | RU2679661C1 (ja) |
| SG (1) | SG11201604944PA (ja) |
| WO (1) | WO2015091833A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201810644TA (en) * | 2016-07-01 | 2018-12-28 | H Lundbeck As | Vortioxetine dosing regimes for fast onset of antidepressant effect |
| US11865112B2 (en) | 2018-11-06 | 2024-01-09 | Purdue Pharma L.P. | Compositions and methods for opioid antagonist delivery |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013740A (en) | 1990-03-22 | 1991-05-07 | Hillel Glover | Method for treating emotional numbness and coma |
| US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| JP2004518654A (ja) * | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US20030087896A1 (en) * | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| HUP0401022A3 (en) * | 2001-08-14 | 2006-11-28 | Biotie Therapies Corp | Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DK1485051T3 (da) * | 2002-03-20 | 2008-09-08 | Euro Celtique Sa | Fremgangsmåde til indgivelse af buprenorphin til behandling af depression |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| EP1954316A1 (en) * | 2005-11-28 | 2008-08-13 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| WO2008066916A1 (en) | 2006-11-30 | 2008-06-05 | The Mclean Hospital Corporation | Methods for the treatment of mood disorders |
| JP5128578B2 (ja) * | 2006-04-04 | 2013-01-23 | エモディス ゲーエムベーハー | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| RS52205B2 (sr) | 2006-06-16 | 2021-05-31 | H Lundbeck A/S | 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| SI2435439T1 (sl) | 2009-05-25 | 2016-06-30 | H. Lundbeck A/S | Priprava nalmefen hidroklorida iz naltreksona |
| US20120302590A1 (en) * | 2009-08-13 | 2012-11-29 | The General Hospital Corporation | Methods and compositions to prevent addiction |
| MA34261B1 (fr) | 2010-04-30 | 2013-05-02 | Takeda Pharmaceutcal Company Ltd | Comprime a delitage intestinal |
| MX2013005009A (es) | 2010-11-05 | 2013-08-01 | Lundbeck & Co As H | Metodo para la elaboracion de naltrexona. |
| JP6406713B2 (ja) | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| WO2014170352A1 (en) | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with anxiety disorder |
| US20160058753A1 (en) | 2013-04-17 | 2016-03-03 | H. Lundbeck A/S | Nalmefene for Treatment of Patients with Mood Disorder |
-
2014
- 2014-12-18 CA CA2933733A patent/CA2933733A1/en not_active Abandoned
- 2014-12-18 WO PCT/EP2014/078515 patent/WO2015091833A1/en active Application Filing
- 2014-12-18 RU RU2016123972A patent/RU2679661C1/ru not_active IP Right Cessation
- 2014-12-18 ES ES14818973.1T patent/ES2694352T3/es active Active
- 2014-12-18 US US15/105,701 patent/US10376506B2/en active Active
- 2014-12-18 KR KR1020167016182A patent/KR20160093025A/ko not_active Application Discontinuation
- 2014-12-18 AU AU2014368548A patent/AU2014368548B2/en not_active Ceased
- 2014-12-18 SG SG11201604944PA patent/SG11201604944PA/en unknown
- 2014-12-18 MX MX2016007947A patent/MX368870B/es active IP Right Grant
- 2014-12-18 CN CN201480069586.5A patent/CN105828821B/zh active Active
- 2014-12-18 EP EP14818973.1A patent/EP3082815B1/en active Active
- 2014-12-18 JP JP2016540981A patent/JP6448645B2/ja active Active
-
2016
- 2016-06-15 IL IL246253A patent/IL246253A0/en unknown
- 2016-06-17 CL CL2016001570A patent/CL2016001570A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252596A0 (en) | History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
| JP2016515522A5 (ja) | ||
| JP2016518337A5 (ja) | ||
| JP2015503422A5 (ja) | ||
| JP2014530840A5 (ja) | ||
| MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| HK1245115A1 (zh) | 口腔奧曲肽與其他治療劑聯合應用 | |
| JP2016535100A5 (ja) | ||
| PL3157522T3 (pl) | Antagonisty muskarynowi i ich kombinacje do leczenia choroby dróg oddechowych u koni | |
| JP2016540026A5 (ja) | ||
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| JP2016540030A5 (ja) | ||
| TWD172918S (zh) | 刀型玩具之部分 | |
| JP2016540019A5 (ja) | ||
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| JP2019518052A5 (ja) | ||
| IL248428B (en) | 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis | |
| SI3236950T1 (sl) | Farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive soli ali estre in amlodipin ali njegove farmacevtsko sprejemljive soli | |
| JP2017516883A5 (ja) | ||
| HRP20180819T1 (hr) | Farmaceutski pripravak sildenafil-citrata u obliku suspenzije namijenjene oralnoj upotrebi | |
| EA201692426A1 (ru) | Комбинации зальтопрофена и миорелаксанта | |
| WO2015195922A8 (en) | Compounds for use in treating acute coronary syndrome and related conditions | |
| TWD166960S (zh) | 遊戲控制器附接器之部分 |